Clinical Trials
9 trialsNCT02061800 2024-06-04
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Columbia University
Phase 1/2 Active not recruiting
NCT00997386 2019-09-09
ALBUM
University of Arizona
Phase 2 Completed
NCT01191749 2017-05-09
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00683046 2016-11-22
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
University of Chicago
Phase 2 Completed
NCT00533923 2016-07-18
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT00578903 2016-04-22
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
Baylor College of Medicine
Phase 2 Terminated
NCT00618969 2016-03-03
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
University of Arizona
Phase 2 Completed
NCT00895739 2013-08-12
Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00056966 2012-06-29
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Baylor College of Medicine
Phase 1/2 Completed